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Abstract
Ali, Remah. M.S. in Biochemistry and Molecular Biology Program, Wright State
University, 2013. Histone Deacetylation as a Mechanism of YPEL3 Down-regulation in
ER-α Positive Breast Cancer Cell Lines.

YPEL3 is a growth inhibitory gene that was established by our laboratory to
trigger senescence in both primary and tumor cells. We recently reported YPEL3 to be
directly repressed by estrogen in estrogen receptor-α positive (ER-α +ve) breast cancer
cell lines. Here, we set out to determine whether the repression of YPEL3 involves
histone deacetylation and, if so, elucidate the molecular mechanism of this activity.
MCF-7, T-47D, and ZR-75.1 (all ER-α +ve) breast cancer cell lines were treated with
varying doses of the global histone deacetylase inhibitors (HDACIs), trichostatin A
(TSA) or suberoyl anilide hydroxamic acid (SAHA), for 24, 48 and 72 hours. Total RNA
was isolated and the YPEL3 gene expression was analyzed by reverse transcriptase–
polymerase chain reaction (RT-PCR) and normalized to glyceraldehyde-3-phosphate
dehydrogenase (GAPDH) gene expression. Senescence was assayed using the senescence
associated β-galactosidase (SA-β-gal) assay. RT-PCR analysis demonstrated an increase
in YPEL3 expression in MCF-7 and T-47D cells treated with TSA or SAHA when
compared to vehicle alone. In MCF-7 cells, this treatment correlated with a marked
increase in cells staining positive for senescence for the 48- and 72- hour time points. The
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observed senescence was specific to YPEL3 as the treatment with HDACIs failed to
induce comparable senescence in MCF-7 cells knocked-down for YPEL3. In this project,
we establish and report one mechanism through which global HDACIs produce their
effect on YPEL3, which is the down-regulation of ER-α mRNA and/or protein levels.
RT-PCR analysis showed that of the two HDACIs, only SAHA reduces ER-α mRNA
levels. In contrast, western blot experiments demonstrated a significant reduction of the
ER-α protein levels in response to both TSA and SAHA following 48-hour treatment.
This is consistent with our previous report of the inhibitory effect of estrogen, mediated
by ER-α, on YPEL3 expression and associated senescence. Further investigation of a
potential repressor complex recruited by ER-α to the estrogen response elements adjacent
to YPEL3 promoter would provide answers as to whether HDACs directly participate in
YPEL3 repression. The identification of epigenetic mechanisms involved in YPEL3
inactivation in ER-α positive breast cancer cell lines is critical for establishing treatment
regimens that specifically target YPEL3 to induce senescence and limit tumor growth and
spreading.
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I. Introduction and Purpose
The YPEL3 Gene
Yippee-like 3 protein (YPEL3) was first identified as small unstable apoptotic
protein (SUAP) that was found to be induced in murine 32Dcl3 myeloblastic cells
actively undergoing apoptosis as a result of interleukin 3 deprivation (S.J Baker, 2003).
Later SUAP received its current designation as YPEL3 due to it being included as a
member of YPEL gene family (YPEL1 through YPEL5) with high homology to the
Drosophila yippee gene. YPEL3 shows high homology at the amino acid sequence level
to its family members (43.8-89.1%) and mouse counterpart Ypel3 (100%) (Table 1).
Human YPEL gene chromosomal locations were revealed with their counterpart mouse
family members identified in the syntenic region of mouse chromosomes (Figure 1A &
B). Human YPEL3 is located on the short arm of chromosome 16 (Figure 1C). In
conclusion, 100 YPEL homologues were identified in 68 species showing Yippee/YPEL
genes to be evolutionarily conserved from slime molds to human (Hosono et al., 2004).
The expression profile of the YPEL family genes in human and mouse was
examined and YPEL3 was found to be constitutively expressed in all the tissues tested. It
was reported to possibly localize to the centrosome during the interphase and to an
unknown structure(s) on or close to the mitotic spindle during the mitotic phase, which
might suggest a role in mitosis during cell division (Hosono et al., 2004).

1

Human
Human
YPEL1
YPEL1

YPEL2

YPEL3

YPEL4

YPEL5

96.6a

8	
   8.2

83.2

49.5

89.1

85.0

48.5

83.9

43.8

YPEL2
YPEL3
YPEL4

44.6

YPEL5

Table 1: Amino acid sequence identities among human YPEL family members.
Human YPEL3 shows high homology to its family members (43.8-89.1%).
a

Identity values were shown as % (modified from Hosono et al., 2004; Table 3).
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(1A)

(1B)

(1C)

Figure 1: Chromosomal locations of the human and mouse YPEL family members.
(A) Chromosomal locations of the human YPEL family members. (B) Mouse Ypel gene
family distribution on chromosomes (Modified from Hosono et al., 2004; Table 2). (C)
YPEL3 is located on the short arm of chromosome 16 (modified from the Weizmann
Institute of Science website).
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NCBI reports a 940-bp YPEL3 transcript (transcript 1) (NCBI Reference
Sequence: NM_001145524.1) that translates into 119 amino acid protein (~ 13.6 KD).
The sequence of this YPEL3 isoform has been chosen as the 'canonical' sequence (Figure
2A) (NCBI Reference Sequence: NP_001138996.1). An alternative 1588-bp YPEL3
transcript (transcript 2) (NCBI Reference Sequence: NM_031477.4) is reported to
translate to an isoform different from the canonical sequence by an additional 39-amino
acid sequence at the N-terminal to make up a 157 amino acid isoform (~ 17.5 KD)
(Figure 2B) (NCBI Reference Sequence: NP_113665.3). In both isoforms, YPEL3
protein has 2 putative zinc finger motives that are also common to all members of the
YPEL family (Figure 1) (Hosono et al., 2004). At least 10 other transcripts have been
identified from different normal and tumor human tissues (NCBI).
YPEL3 is a p53 Target Gene
Our laboratory’s interest in YPEL3 originated from a microarray experiment in
which p53 was reactivated using RNAi approaches to knockdown the two negative
regulators of p53, HdmX (human double minute x) or Hdm2 (human double minute 2), in
MCF7 human breast carcinoma cells. YPEL3 was found to be up-regulated upon this
non-genotoxic stress induction of p53 (Heminger et al., 2009). Later, additional
validation studies including chromatin immunoprecipitation (ChIP), confirmed YPEL3 to
be a novel p53-target gene. Based on a bioinformatic screen, two putative p53 binding
sites were identified, one approximately 1.3 kbp in the 5’ region of the YPEL3 promoter
(where p53 binds in 2 half-sites) and a second site immediately next to the YPEL3
promoter (where p53 binds in 3 half-sites) as shown in Figure 3 (Kelley et al., 2010).

4

Figure 2: Human YPEL isoforms. Schematic representation of the canonical 119amino acid YPEL3 protein isoform 1 (A) and the alternative 157-amino acid YPEL3
isoform 2 (B). Zinc finger domains are shown in rectangles for both isoforms (modified
from NCBI website).
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Figure 3: YPEL3 is a p53-target gene. Schematic showing the layout of the YPEL3
gene with putative p53 binding sites indicated by * as determined by p53MH algorithm
(modified from Kelley et al., 2010; Figure 2A).
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YPEL3 Activation Leads to Cellular Senescence in both Primary and Tumor Cells
After demonstrating YPEL3 was a p53-inducible gene, our laboratory sought to
test the biological effect of human YPEL3 induction. Viral transduction experiments
were employed to infect MCF7 breast carcinoma cells and U2OS osteosarcoma cells
expressing the TetR repressor protein with lentivirus carrying the YPEL3 tetracyclineinducible (tet-on) lentiviral YPEL3-V5-tagged expression construct. Using a colony
formation assay, both MCF-7 and U2OS cells showed considerably fewer viable colonies
when expressing YPEL3 as compared to control cells. These experiments demonstrated
that YPEL3 induction to physiologically relevant levels inhibits cell growth (Kelley et al.,
2010). As mentioned earlier, mouse YPEL3 (SUAP) was reported to inhibit cell growth
by means of apoptosis in murine myeloid precursor cells (S.J Baker, 2003). However,
human YPEL3 did not show a consistent apoptotic response as assayed by sub-G1 or
caspase-3 activation (both are indicators of programmed cell death).
In contrast, YPEL3 over-expression experiments through viral transduction and
controlled tet-regulated expression to induce physiologically relevant levels (comparable
to YPEL3 levels as a result of p53 activation) strongly showed that YPEL3 induction
triggers premature cellular senescence in both human primary IMR90 diploid fibroblasts
and human tumor MCF-7 and U2OS cells. This was assayed by the senescence associated
β-galactosidase (SA-β-gal) assay, where senescent cells show increased β-galactosidase
activity at acidic conditions (pH = 6) and confirmed by the appearance of senescenceassociated heterochromatin foci (SAHF) within the nuclei of senescent cells (Kelley et
al., 2010).
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YPEL3 Is Down-regulated in Human Tumors
After YPEL3 was established to be a p53-regulated gene with the ability to trigger
premature cellular senescence in both normal and tumor cells, our laboratory sought to
investigate its possible down-regulation in human tumors. Eight different human cancer
types in a TissueScan survey plate (CSRT101, OriGene) were examined for YPEL3
messenger RNA (mRNA) expression using multiplex TaqMan RT–PCR and normalizing
to glyceraldehyde-3-phosphate dehydrogenase (GAPDH) mRNA expression. YPEL3 was
found to be significantly down-regulated in three of the eight tumor types: colon, lung
and ovarian. In the colon cancer set, YPEL3 relative mRNA levels were decreased in all
nine tumor samples as compared to their three respective normal specimens. Within the
same survey plate, YPEL3 mRNA expression was also decreased in eight of the nine
lung tumor samples and in all of the ovarian tumor samples compared to their normal
controls. Two larger screens in ovarian cancer and colon cancer tissues showed a
significant decrease in YPEL3 relative mRNA expression in 30 ovarian tumors relative to
6 normal samples (Kelley et al., 2010) and 20 of 22 collected colon tumor tissues
compared to their matched, normal mucosa (Tuttle et al., 2011).
Mechanisms of YPEL3 Inactivation in Different Human Cancers
Having established YPEL3 to be a novel p53-senescent activator that is downregulated in various human tumors, investigators in our laboratory examined the potential
mechanisms of YPEL3 down-regulation in these tumors. Understanding the mechanisms
of YPEL3 repression in tumor cells could prove invaluable in anti-cancer drug research
because induction of tumor cell senescence may represent a therapeutic approach for
8

cancer patients. Our laboratory has extensively investigated and confirmed specific
patterns of epigenetic silencing of YPEL3 in two types of human tumors, ovarian and
colon.
Epigenetic Regulation of YPEL3 in Human Tumors
Epigenetic processes can be described as mitotically and/or meiotically heritable
alterations in gene expression that take place during development and somatic cell
proliferation, without any change in the coding sequence (Riggs et al., 1996). So unlike
genetic alterations, epigenetic mechanisms are reversible which make them extremely
interesting for therapeutic approaches (Yoo et al., 2006). Epigenetics has rapidly evolved
as an area of cancer research because it was found to contribute to the development and
progression of cancer by inactivation of certain tumor-suppressor genes and/or activation
of oncogenes through remodeling of chromatin architecture. Epigenetics takes the form
of at least two main mechanisms: DNA hypermethylation and histone deacetylation
(Egger et al., 2004).
DNA Hypermethylation
DNA methylation is a process that occurs by covalently adding a methyl group at
the 5' carbon of the DNA cytosine ring (Bird A, 2002). The process of demethylation is
believed to be an enzymatic reaction catalyzed by DNA methyltransferases (DNMTs)
(Bhattacharya et al., 1999).
Methylation of mammalian DNA occurs primarily at cytosine-guanosine
dinucleotides (CpGs) rich sites, termed CpG islands. These islands extend about 0.5–3
kbp and are found in almost half of all human genes in the regulatory regions of gene
9

promoters, where transcription is initialed. DNA hypermethylation of CpG islands is
usually associated with silencing of gene expression. This is because upon the
methylation of the cytosines in these islands, the methyl groups of the resultant 5methylcytosines project into the major groove of DNA to suppress the expression of the
gene (Antequera et al., 1993; Herman et al., 2003). In contrast, loss of methylation often
leads to gene reactivation and is believed to be actively mediated by a different type of
enzymes described as DNA demethylases (Fremont et al., 1997; Bhattacharya et al.,
1999).
Aberrations of DNA methylation processes may ultimately contribute to cancer
development through the epigenetic inactivation of certain cancer-related genes by
promoter hypermethylation (Baylin et al., 2006). Genes affected in such case include
tumor suppressor genes, such as the cell cycle checkpoint genes, p21WAF1/CIP1 and
p16 INK4a, and genes regulating growth in the cell, such as RAS association domain family
1A (RASSF1A) and retinoic acid receptor β (RARβ). In addition, oncogene activation by
promoter hypomethylation may contribute to the processes of carcinogenesis. Abnormal
DNA methylation occurs at specific genes in almost all neoplasms and there is evidence
that the methylation status of various cancer types might have important implications in
prognosis, clinical monitoring, risk assessment, and even therapeutic approaches (Esteller
et al., 2000; Nguyen et al. 2000; Wong et al. 2000; Chim et al., 2001; Gaudet et al.,
2003).
During the initial steps of searching the possible mechanisms of YPEL3 downregulation in human tumors, investigators from our laboratory analyzed the YPEL3
promoter and uncovered a 950-bp CpG island that extends from -8 to -1222 relative to
10

the transcription start site, suggesting that YPEL3 down-regulation may be occurring
through CpG hypermethylation. Indeed, when three different human ovarian cancer cell
lines A2780 (harboring wild-type p53), Cp70 (null for p53), and C30 (p53 mutant) were
treated with increasing doses of the DNA methyltransferase inhibitor 5-azadeoxycytidine,
a significant increase in YPEL3 gene expression was observed. This was further
confirmed when the genomic DNA from Cp70 cells treated with 5-azadeoxycytidine was
subjected to bisulfate treatment and a significant decrease in the hypermethylation of the
YPEL3 CpG island was observed. Altogether, the molecular basis of YPEL3 downregulation in ovarian cancer cell lines was established to be DNA hypermethylation of
the CpG island immediately upstream of the YPEL3 promoter (Kelley et al., 2010).
Histone Deacetylation
Histones comprise the protein backbone of chromatin. At physiological
conditions, DNA is negatively charged and binds to the positively charged ε-amino
groups of lysine residues on histones. Acetylation of these ε-amino groups diminishes
their positive charge and, in turn, their ability to bind to negatively charged DNA. The
deacetylation process is catalyzed by histone acetyltransferases (HATs) and results in an
open chromatin configuration, which provides access for transcription factors and the
general transcription machinery. On the other hand, deacetylation processes remove the
acetyl groups from histone lysine residues. This restores the positive-negative interaction
between ε-amino groups and DNA, allowing compacted chromatin to form and prevent
the recruiting of transcription machinery and resulting in transcriptional repression.
Deacetylation processes are catalyzed by a distinct type of enzymes called histone
deacetyltransferases (HDACs) (Glozak et al., 2007).
11

The imbalance between acetylation and deacetylation processes, ultimately
affecting transcription activation and deactivation, may be associated with tumorigenesis
as indicated by several lines of evidence. In particular, HDACs have been reported to
associate with a number of well-characterized cellular oncogenes and tumor suppressor
genes contributing to the development of many specific forms of malignancy (HessStumpp et al., 2005; Fukuda et al., 2006; Lin et al., 2006).
Eukaryotic cells have been reported to have 18 distinct HDACs that reside either
in the nucleus or the cytoplasm (Gallinari et al., 2007, Cang et al., 2009). According to
phylogenetic analyses and sequence homologies with yeast proteins, HDACs are
classified into four categories. Class I family members include HDAC1, HDAC2,
HDAC3 and HDAC8. They are related to HDACs in yeast and strictly localize inside
cellular nuclei (Gregoretti et al., 2004; Brosch et al., 2008). Class II family of HDACs
consists of HDAC4, HDAC5, HDAC6, HDAC7, HDAC9 and HDAC10 proteins, which
are similar to Hos3 in yeast. They are primarily localized in the cellular cytoplasm and
shuttle to the nucleus under certain conditions (Fischle et al., 2001; Yang et al., 2005).
HDAC class IV has only one member, HDAC11, which is located in both cytoplasm and
nucleus of the cell (Gao et al., 2002). Members of Class I, II, and IV have been reported
to share a common mechanism of catalysis, the Zn-catalyzed hydrolysis of the acetyllysine amide bond (de Ruijter et al., 2003). Finally, Class III family of HDACs is the
called the SIRTs, which include seven members SIRT1 through SIRT7. As the name
implies, these proteins are similar to yeast SIRTs. They differ from Classes I, II, and IV
in that they are not Zn-dependent and rather employ NAD as a cofactor (Marks et al.,
2001).
12

HDAC inhibitors (HDACIs) have recently been developed as a new therapeutic
class of drugs for the treatment of different human cancers (Bieliauskas et al., 2008;
Papeleu et al., 2005; Yoshida et al., 2003; Kouraklis et al., 2002; Walkinshaw et al.,
2008). Based on their chemical structure, HDAC inhibitors are divided into four classes:
the hydroxamates, the cyclic peptides, aliphatic acids and the benzamides (Dokmanovic
et al., 2005). Trichostatin A (TSA), which belongs to the hydroxamate class, was the first
compound reported to display HDAC inhibitor properties in 1990. Later, suberoyl anilide
hydroxamic acid (SAHA), a structural analogue of TSA, was the first HDAC inhibitory
agent to be approved by the FDA for treating cutaneous T-cell lymphoma (CTCL) in
cases of relapses, following two systemic therapies, or in patients with progressive or
persistent disease. More than eleven different HDAC inhibitors are currently being tested
in at least 80 clinical trials including both hematological and solid malignancies,
highlighting the importance of histone deacetylation as a potential target pathway for
cancer therapy (Tan et al., 2010).
Given that YPEL3 was established to be down-regulated in ovarian cancer cell
lines by means of DNA hypermethylation of the CpG island upstream of the YPEL3
promoter (Kelley et al., 2010), investigators from our laboratory examined DNA
hypermethylation as a potential mechanism of YPEL3 down-regulation in 20 of 22
collected colon tumor tissues with documented YPEL3repression compared to their
normal, matched mucosal specimens. None of the samples demonstrated differential
methylation between the normal mucosa and colon tumor tissues. Further, cell culture
experiments were utilized to investigate DNA hypermethylation being involved in
YPEL3 repression in colon cancer cell lines. For this purpose, Caco-2 and HCT116-/13

p53 colon carcinoma cells were treated with increasing doses of the DNA
methyltransferase inhibitor, 5-azadeoxycytidine. YPEL3 expression was only modestly
increased in Caco-2 cells and no increase was observed in HCT116-/- p53 cells upon 5azadeoxycytidine treatment, suggesting that DNA hypermethylation may not be a
significant form of YPEL3 regulation in colon carcinoma cell lines or tissues (Tuttle et
al., 2011). Consequently, our laboratory looked into the possible involvement of histone
deacetylation in YPEL3 repression in colon cancer cell lines. Caco-2 and HCT116 cells
were treated for 24 hours with increasing doses of the global HDAC inhibitor TSA,
which inhibits Class I & II HDACs (Dokmanovic et al., 2007). It was reported that for
both Caco-2 and HCT116 cells, inhibiting histone deacetylation triggered elevated
YPEL3 gene expression approximately 4-fold when compared to untreated cells.
Therefore, histone acetylation may be playing a role in the regulation of YPEL3 in colon
cancer cell lines and human colon adenocarcinoma (Tuttle et al., 2011).
YPEL3 Regulation in Breast Cancer
Having established YPEL3 down-regulation in certain human tumor types and
examining the possible epigenetic mechanisms of its repression, investigators from our
laboratory most recently studied YPEL3 gene regulation in breast cancer. This originated
following a comprehensive genome-wide analysis in estrogen stimulated MCF-7 and ZR75.1 cells which reported YPEL3 as an estrogen repressed gene (Cicatiello et al., 2010).
To determine if estrogen was playing a regulatory role in YPEL3 mRNA expression,
various breast cancer cell lines were grown in charcoal-stripped serum (CSS) in this
study, i.e. in the absence of estrogen. MCF-7 and ZR-75.1 breast carcinoma cells (both
express the estrogen receptor alpha (ER-α) and wt p53) as well as T-47D ductal
14

carcinoma cells (ER-α positive, mutant p53) grown in CSS for 3-5 days, up-regulated
their YPEL3 mRNA expression as compared to cells grown in complete media. In
contrast, the ER-α negative SkBr-3 breast carcinoma cells grown in CSS showed no
induction of YPEL3 gene expression. This suggested that estrogen repression of YPEL3
in ER-α positive breast cancer cell lines was ER-α dependent. A subsequent experiment
showed that MCF-7 cells knocked-down for ER-α elevate their YPEL3 mRNA levels to
parallel that following CSS treatment, confirming that YPEL3 repression by estrogen
occurs through its receptor alpha. The observed induction of YPEL3 expression in T-47D
cells (which are p53 mutant) implied the independence of this effect on p53. This was
further supported by that fact that growing MCF-7 cells knocked-down for p53 in CSS
induced YPEL3 expression. This study lastly reported that blocking estrogen signaling in
ER-α positive breast cancer cell lines triggered YPEL3-dependent cellular premature
senescence, with these findings being in line with previously reporting YPEL3 induction
to trigger cellular senescence in tumor cells (Tuttle et al. 2012).
While a complete estrogen response element (ERE) within 5 kbp of the
transcriptional start site of YPEL3 could not be identified, an earlier
immunoprecipitation-paired end diTag cloning and sequencing study described YPEL3 to
be a repressed by estrogen and to harbor an ERE 30 kbp upstream of its promoter (Lin et
al., 2007). Further, an additional ERE half site has been identified about 3.6 kbp in the 3’
un-translated region (UTR) of the YPEL3 gene (Figure 4) (unpublished, R. Ali). The
presence of these ER-α binding sites is suggesting of a direct repression of YPEL3
expression by the potential formation of a co-repressor complex recruited by the estrogen
bound ER-α as homodimers to the complete distant ERE or heterodimers to the closer
15

Figure 4: Schematic of the human YPEL3 gene on chromosome 16. Transfac
identification of the putative ERE is within the 3’ UTR region of exon 4 (unpublished, S.
Berberich; R. Ali).
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ERE half-site. Altogether, YPEL3 repression by estrogen represents a significant
finding and the characterization of key members in the pathway of estrogen-mediated
YPEL3 repression may uncover potential targets for drug therapy to activate YPEL3
function in inducing senescence in these cancer cells (Tuttle et al. 2012).
Purpose of the Study
The estrogen receptor has been reported to mediate target gene transcription
repression through the formation of stable co-repressor complexes (Yu et al., 2003). This
function is mediated by multiple mechanisms, which involve histone deacetylation of
lysine residues by HDACs contained in large co-repressor complexes. Current models
indicate these complexes first bind the acetylated histones, deacetylate their tails, and
then show increased affinity for the deacetylated chromatin, ultimately enhancing gene
repression by increased association (Yu et al., 2003; Stanya and Kao, 2009). With recent
data from our laboratory suggesting a direct inhibition of the YPEL3 gene by estrogen, in
addition to our previous reports of the epigenetic mechanisms, particularly histone
deacetylation, contributing to YPEL3 repression in human cancer tissues and cell lines,
we hypothesize that estrogen bound ER-α is recruiting a co-repressor complex with the
participation of a histone deacetylase (HDAC) at the promoter of YPEL3 to repress its
expression. This dissertation is designed to investigate the possible involvement of
histone deacetylation in ER-α repression of YPEL3, and if present elucidate the
molecular mechanism of its occurrence. The identification of mechanisms of YPEL3
repression mediated by the estrogen receptor alpha will provide insight into potential
treatment regimens to reactivate this gene to trigger senescence in breast cancer cells.
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II. Materials and Methods
Cell Lines, Antibodies and Reagents
Human tumor cell lines, MCF7 (breast carcinoma), T-47D (ductal carcinoma) and
ZR-75.1 (breast carcinoma) were grown in Dulbecco’s Modified Eagle’s Medium
(DMEM; Thermo Scientific) supplemented with 10% fetal bovine serum (FBS; Atlanta
Biologicals) and 10 µg/mL gentamicin unless otherwise specified. When noted, MCF-7
cells were grown in DMEM supplemented with 10% charcoal/dextran stripped fetal
bovine serum (Atlanta Biologicals). The human tumor cell line SkBr-3 (breast
carcinoma) was grown with in Roswell Park Memorial Institute’s 1640 medium 1X
(RPMI-1640 Medium 1X; Thermo Scientific) supplemented with 10% FBS, 1X
minimum essential medium non-essential amino acids (MEM NEAAs; Invitrogen), 1
mM sodium pyruvate (Invitrogen), 2 mM L-glutamine (Invitrogen) and 10 µg/mL
gentamicin unless otherwise specified.
Histone deacetylase 3 (Sigma) polyclonal antibody was used as indicated.
Estrogen receptor-α (Santa Cruz Biotechnology, Inc.) and β-actin (Sigma) monoclonal
antibodies were also used as indicated. Horseradish peroxidase (HRP)-conjugated antimouse or anti-rabbit secondary antibodies (Promega) were utilized in conjunction with
Super Signal substrate (Pierce) for chemiluminescence detection of proteins.
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Global histone deacetylase inhibitors (HDACIs) trichostatin A (TSA) and
suberoyl anilide hydroxamic acid (SAHA) were purchased from Cayman Chemical. 1 mg
of TSA was dissolved in 6.62 ml of DMSO (dimethylsulfoxide) which is the solvent
recommended by the manufacturer, to create a 0.5 mM stock solution (TSA FW = 302.4).
This TSA stock was aliquoted into 0.5 ml aliquots and stored at -20°C until use. Repeated
freezing/thawing of the same TSA tube affected its activity, where it produced no effects
after 20 freeze/thaw cycles. Therefore, TSA tubes were disposed of every 10-15
freeze/thaw cycles. 5 mg of SAHA were dissolved in 18.90 ml DMSO (solvent
recommended by the manufacturer) to create a 1 mM stock solution (SAHA FW =264.3).
This SAHA stock was aliquoted into 1 ml aliquots and stored at -20°C until use. Unlike
TSA, repeated freezing/thawing of an SAHA tube did not seem to affect the activity of
this chemical, at least for 20 freeze/thaw cycles.
Lentiviral Generation and Infection
The ViraPowerTM Lentiviral Expression System was purchased from Invitrogen
and was used to generate replication incompetent, HIV-1 based lentivirus which was then
used to deliver and express genes of interest (all shRNAs) into dividing mammalian
tumor cells. Instructions supplied with the kit, with only minor modifications, were
followed to generate the desired lentivirus. The basic layout involved the transfection of
approximately 5 million 293FT cells using Lipofectamine 2000 (Invitrogen) overnight
with ViraPowerTM packaging mix in addition to the gene of interest cloned into pLKO.1
plasmid. pLenti plasmids used for experiments in this project are listed in Table 2.
Sixteen to twenty-four hours later, the transfection mixture was removed and 11 mL of
complete growth media with no antibiotics (DMEM containing 10% FBS, 1X MEM
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Lentiviral Plasmid

Antibiotic Resistance

Company

pLKO.1-shCON

Puromycin

Addgene; Plasmid 1864

pLKO.1-shYPEL3_UTR

Puromycin

Sigma

pLKO.1-shHDAC3

Puromycin

Sigma

Table 2: Lentiviral plasmid name, antibiotic resistance and company.
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NEAAs, 1mM Sodium Pyruvate and 2 mM L-Glutamine) added. The supernatant
containing the lentivirus was harvested approximately 24 hours post-transfection and

centrifuged at 3000 rpm for 15 minutes at room temperature to pellet cells and debris.
Lentiviral supernatant was aliquoted into 1 mL aliquots and stored at -80°C until time of
use.
To infect MCF-7 breast carcinoma cells, lentiviral supernatant was thawed at
room temperature and added to regular cell culture media containing 6 µg/mL Polybrene
(Santa Cruz Biotechnology). Cells were incubated with the previous Polybrene/complete
media mixture for 18-24 hours, and then this infection cocktail was removed and replaced
with complete media. If cells were selected, Puromycin was added to the complete media
at a concentration of 1 µg/mL and selection continued for 4-6 days until the control plate
of uninfected cells were dead. Puromycin was employed for selection because all viruses
used for experiments in this project were pLKO sh-viruses. Puromycin kill curve for
MCF-7 cell line was previously determined by Kelly Miller as 1 µg/mL (BMS Thesis).
All steps were performed under BSL2+ recommended Federal and institutional
guidelines following an institutional bio-safety committee approved protocol.
RNA Isolation and Reverse Transcription of mRNA
Cells were plated at various densities depending on type of treatment: cells to
receive TSA/ SAHA/ CSS treatment were seeded at a relatively high density (400,000 to
500,000 cells per (6-cm) dish or well in (6-well) plates), whereas cells to be infected with
shCON/ shHDAC3/ shYPEL3, given DMSO treatment or be grown in regular cell culture
media were plated at a lower density of approximately 150,000 cells per (6-cm) dish or
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well in (6-well) plates. E.Z.N.A TM Total RNA Kit I for RNA isolation was purchased
from Omega Bio-Tek and cells were rinsed once in Dulbecco’s Phosphate Buffered
Saline (DPBS) prior to lysis. Next cells were lysed on the culture plate with TRK Lysis
Buffer from the previous kit supplemented with β-mercaptoethanol (20 µL of βmercaptoethanol per 1 mL of TRK Lysis Buffer). Wells in (6-well) plates and (6-cm)
plates were lysed using 350 µL of β-mercaptoethanol-TRK Lysis Buffer mixture,
whereas (10-cm) cell culture plates were lysed using 700 µL of the previous mixture.
Total RNA was isolated following instructions supplied with the kit, and 40 µL of
diethylpyrocarbonate (DEPC)-treated water (from kit) was used for total RNA elution at
all times. The RNA from all samples was quantified using the NanoDrop ND-1000
spectrophotometer. One µg of each total RNA sample was used for reverse-transcription
reaction with random hexamers to produce complementary DNA (cDNA) using the
qScriptTM cDNA SuperMix Kit (Quanta Biosciences) according to manual’s instructions.
The reverse transcription (RT) reaction was performed in an Applied Biosystems Gene
Amp PCR System 2700. The RT conditions include an initial 10 minute incubation step
at 25°C, a 30 minute RT step at 48°C, a 5-minute inactivation step at 95°C, and an
infinite hold at 4°C. cDNA from the RT reaction was diluted in 200 µL of sterile DNAsefree water.
Quantitative RT-PCR
Quantitative real-time PCR was performed in a 96-well microliter plate format on
an ABI 7900HT Sequence Detection System. In each well on the 96 well plate, a 20 µL
reaction was set up by mixing 9 µL of H2O-diluted cDNA, 1 µL of Assay-on-Demand
Gene Expression product (Applied Biosystems; contains primers and a fluorescent
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Taqman probe) designed for the gene of interest, and 10 µL of 2X TaqMan Gene
Expression Master Mix (purchased from Life Technologies). The ABI 7900HT Sequence
Detection System was programmed as follows: 2 minute hold at 50°C, 10 minute hold at
95°C followed by 40 cycles of a 15 second 95°C denaturing step and a 1 minute 60°C
anneal and elongation step. Each cDNA sample was normalized to the internal control of
GAPDH and analyzed in triplicate for target gene expression. Relative changes in
specific gene expression were determined by determining the fold change (RQ) relative
to the control sample using SDS 2.4 software (ABI). The mean RQ values are plotted and
the error bars represent 95% confidence intervals.
Western Blot Analysis
Cells were plated at various densities depending on the type of treatment as
described above: cells to receive TSA/SAHA treatment were seeded at a relatively high
density (400,000 to 500,000 cells per (6-cm) dish or well in (6-well) plates), whereas
cells to be infected with shCON/ shHDAC3, given DMSO treatment or grown in regular
cell culture media were plated at a lower density of approximately 150,000 cells per (6cm) dish or well in (6-well) plates. In occasions of TSA/SAHA treatment where
significant cell death was observed, multiple (6-cm) dishes/wells in (6-well) plates were
set up for each TSA/SAHA treatment condition and then lysates were combined in one
sample in order to reach a total protein concentration of 25 µg in a maximum of 50 µL
final volume for loading.
Cells were harvested for western blotting by removing media, washing twice with
DPBS and then scraping the cells into 1 mL of DPBS. The cell suspension was
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transferred into a 1.7 mL microcentrifuge tube and cells were pelleted by spinning the
tubes at 4°C (using refrigerated microfuge) at 10,000 rpm (8,161 x g) for 2 minutes.
Supernatant DPBS was aspirated without perturbing the cell pellets and then these pellets
were stored at -80°C until use.
To prepare total cell lysates, the cell pellet was thawed on ice in 25-100 µL lysing
buffer (50 mM tris, 5mM EDTA, 150 mM NaCl, 0.5% NP.40, pH=8.0) mixed with
protease inhibitor cocktail (PIC) (Sigma) where 1 mL of lysing buffer was supplemented
with 10 µL of protease inhibitor cocktail. Once thawed, the cell pellet was re-suspended
by pipetting to lyse the cells and then incubated on ice for a total of 30 minutes to
complete the lysis process. The lysates were then centrifuged in a refrigerated microfuge
at 14,000 rpm (15,996 x g) for 10 minutes, and the supernatant containing the soluble
proteins was transferred to a new 1.7 mL microcentrifuge tube. Bradford protein assay
was used to calculate protein concentration for each of the samples as follows: 1 µL of
the whole cell extract was mixed with 799 µL of sterile distilled water (SDW), and then
200 µL of Bradford reagent (Bio-Rad Inc.) were added. Bovine serum albumin (BSA)
was used to generate a standard curve by mixing 1-15 µg of BSA with 800 µL SDW and
200 µL Bradford reagent. The absorbance at 595 nm was measured for the protein lysates
on a Thermo Spectronic Genesys 6 spectrophotometer, and the standard curve generated
was used to determine the protein concentration for each sample using its absorbance
value. Twenty-five µg of total protein in 1X SDS loading dye (diluted from 6X SDS
loading dye; 1X = 60 mM Tris, 2% SDS, 10% glycerol, 5% β-mercaptoethanol, 1%
bromophenol blue, pH=7.6) was heated at 70°C for 3 minutes prior to loading on a 12%
sodium dodecyl sulfate (SDS) polyacrylamide gel using a vertical gel electrophoresis
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system. The gel was run at 150 volts for the stacking layer and 200 volts for the
separating layer in 1X SDS running buffer (25 mM Tris, 250 mM glycine, 0.1% SDS, pH
= 8.3) until dye reached the end of gel (2-3 hours). The proteins were transferred onto a
polyvinylidene difluoride (PVDF) membrane (Millipore) pre-soaked in 100% methanol
for 10 seconds, followed by transfer buffer (25 mM tris, 192 mM glycine, 20% methanol,
pH 8.3) for 2 minutes. Protein-membrane transfer was performed in transfer buffer using
a Bio-Rad transfer system for 60 minutes at a constant 100 mA. Subsequently, the
membrane was dried away from light for at least 16 hours, and then incubated in 20 mL
blocking buffer (1X tris buffered saline (TBS), 5% non-fat dry milk (NFDM), 0.1%
Tween-20) on a shaker at 4°C overnight. Probing with the appropriate primary antibody
was performed by incubating the blot in a 1:1,000-1:10,000 diluted solution of the
primary antibody in blocking buffer overnight at 4°C (or at room temperature for 4
hours). Afterwards, the protein membrane was washed 3-4 times in 1:5 blocking buffer in
TBS by shaking at room temperature for 10-15 minutes for each wash. The appropriate
secondary antibody (goat anti-mouse or goat anti-rabbit, both from Promega) was applied
by shaking the blot at 1:5,000 diluted solution of the antibody in 1:5 blocking buffer in
TBS for 45 minutes at room temperature. The blot was subjected to a final round of three
successive washes by shaking for 15 minutes in 1:5 blocking buffer in TBS for each wash
at room temperature. For protein visualization, the blot was exposed to Thermo Scientific
SuperSignal West Pico Chemiluminescent Substrate for 2-3 minutes and protein bands
were visualized on a FUJI FILM LAS 3000 image reader. If necessary, the blot was
shaken in western stripping buffer (25 mM glycine, 1% SDS, pH 2.0) for 20 minutes at
room temperature to remove the antibodies, then the membrane was blocked and
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immunoblotted using another antibody following the same procedure outlined above.
Protein levels were quantified using Image Quant software where the pixel values
representing the protein band intensity were subtracted from the pixel value for the
background. These values were then normalized to the corresponding β-actin band
intensity, measured using the same technique.
Senescence Associated β-Galactosidase Assay and Nuclear Staining
A β-galactosidase staining kit (Millipore Co.) was purchased and used to stain
MCF-7 cells following the manual’s instructions. Prior to staining, cells were first rinsed
with DPBS and then 1X fixation buffer was prepared by diluting the 100X stock from the
kit with PBS. Cells were fixed by adding 1X fixation buffer for 15 minutes at room
temperature per manufacturer’s instructions. Fixing solution was then removed by rinsing
the cells two times using DPBS. MCF-7 cells were then stained by applying 1X staining
solution, and incubating at 37°C with no CO2 for 8 hours. Staining solution was then
removed and cells were rinsed twice with DPBS, then the nuclear DNA in these cells was
stained using Hoechst dye (bis-benzimide; Anaspec Inc.) at a concentration of 25 µg/mL.
This was done by adding the Hoechst dye to DPBS, incubating at room temperature for
10 minutes, and then rinsing twice with DPBS prior to preserving in 70% glycerol. The
preservation step was performed by adding 1 ml of 70% glycerol for each (6-cm) plate or
well in (6-well) plates, sealing the plate with paraffin wrap, and finally wrapping the
plates with foil. Plates were stored at 4°C for a maximum of 2 months for reference and
pictures were taken during the first 2 weeks of storage.
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Olympus 1X70 fluorescence microscope was utilized to visualize cells under
brightfield at 10X magnification. At least three images from three different regions in the
plate were taken using the MagnaFIRE 2.1C software. The total number of cells and
number of blue (β-galactosidase positive) cells were scored for each image by counting at
least one hundred blue cells per treatment condition.
The total number of cells for every bright field image taken for determining the
number of senescent cells was determined by counting the nuclei in that field. Nuclei
were visualized under UV using fluorescence microscopy on an Olympus 1X70
fluorescence microscope at 10X magnification. Images were captured using MagnaFIRE
software 2.1C and the total number of nuclei was counted for each image. The percentage
of β-galactosidase positive cells was determined for each treatment condition by dividing
the number of blue cells by the total number of nuclei for each image.
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III. Results
A. Global HDACI Treatment Induces YPEL3 mRNA Expression in MCF-7 and T-47D
Breast Cancer Cells
As previously described, YPEL3 is repressed by estrogen in ER-α positive breast
cancer cell lines in an ER-α dependent and p53-independent manner. The presence of an
estrogen response element (ERE) with 2 half-sites 30 kbp upstream of the transcription
start site as well as an ERE with one half site 3.6 kbp downstream of the transcription
start site in the 3’ untranslated region (UTR) of the gene is suggestive of a direct estrogen
repression through either/both of these binding sites. To investigate the potential
involvement of histone deacetylation in estrogen repression of YPEL3, MCF-7 breast
carcinoma cells (ER-α positive, wt p53), T-47D ductal carcinoma cells (ER-α positive,
mutant p53), and ZR-75.1 breast carcinoma cells (ER-α positive, wt p53) were treated
with the two global histone deacetyltransferase inhibitors (HDACIs): trichostatin A
(TSA) and suberoyl anilide hydroxamic acid (SAHA) using various dosage regimens.
Total RNA was isolated and YPEL3 mRNA was examined by Taqman-based RT-PCR,
normalized to glyceraldehyde-3-phosphate dehydrogenase (GAPDH) mRNA, and then
compared to that of the vehicle (DMSO) or complete media (CM) treated cells. TSA and
SAHA both belong to the hydroxamate chemical group and are described as global
HDAC inhibitors because they target Class I and II HDACs for inhibition with a nmol/L
potency for TSA and µmol/L potency for SAHA (Dokmanovic et al., 2007).
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TSA has been reported to arrest cell cycle progression in G1 phase and inhibit the
activity of the HDAC1 with an IC50 value of 70 nM in human Jurkat T cells (Marks et al.,
2007). SAHA, on the other hand, inhibits Class I and Class II HDACs at around 50 nM
and arrests cell growth in a wide range of transformed cells in vitro at 2.5-5.0 µM with an
IC50 <100 nM against purified HDAC1(Sawa et al., 2001; Huber et al., 2011).
Accordingly, I designed various dosage regimens for the treatment of MCF-7, T-47D and
ZR-75.1 cells with the HDACIs as illustrated in Table 3. Since TSA and SAHA have
been reported in many studies to induce apoptosis in transformed cells in culture through
multiple mechanisms (Dokmanovic et al., 2007), it was necessary to plate cells
accordingly: cells to be treated with HDACIs were seeded at a high density (400,000 to
500,000 cells) whereas cells to be treated with the vehicle DMSO or grown in CM were
plated at (150,000 cells). Due to HDACI-induced cell death, multiple plates were set up
for one HDACI treatment condition, and RNA lysates were pooled into one sample
during RNA isolation, in order to get sufficient mRNA for RT-PCR experiments.
The first dosage regiment I used consisted of the TSA doses: 25 nM, 70 nM and
280 nM and SAHA doses: 0.5 µM and 5 µM as outlined in Figure 5A. Twenty-four hours
after single-dose treatment, YPEL3 expression was induced 2-fold, 6-fold and 3-fold in
response to 70 nM TSA, 280 nM TSA and 5 µM SAHA, respectively (Figure 5B). T-47D
and ZR-75.1 cells failed to show a comparable YPEL3 mRNA induction after 24 hours of
treatment (Figures 5C & 5D). Because the smaller TSA/SAHA doses in the previous
experiment (25 nM TSA and 0.5 µM SAHA) did not induce YPEL3 expression in MCF7 cells, these doses were eliminated and a new dosage regiment was tried where I added
two doses of SAHA (5 µM and 25 µM) in addition to the original 1 µM SAHA dose.
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Treatment
regimen

DMSO

TSA doses

SAHA doses

25

70

280

nM

nM

nM

Single dose 24A

10 µl

Single dose 24B

10 µl

70 nM

280 nM

1 µM

5 µM

25 µM

24 hours

Single dose 48

10 µl

70 nM

280 nM

1 µM

5 µM

25 µM

48 hours

Single dose 72

10 µl

70 nM

280 nM

1 µM

5 µM

25 µM

72 hours

10 µl

70 nM

280 nM

1 µM

5 µM

25 µM

48 hours

10 µl

70 nM

280 nM

1 µM

5 µM

25 µM

72 hours

Chronic dosing
48
Chronic dosing
72

0.5µM

5µM

Duration
24 hours

Table 3: Dosage regimens for HDACI treatment of MCF-7, T-47D, and ZR-75.1
cells. In single dose 24A, 24B, 48, and 72, cells were plated in (6-well) plates and each
well received one sort of treatment. Cells were administered a single dose of DMSO,
TSA, or SAHA, then total RNA was isolated after time indicated in duration. In Chronic
dosing 48 and 72, each one well of cells in (6-well) plates was treated every 24 hours
with the respective dose of DMSO, TSA, or SAHA. Total RNA then was isolated after
the time indicated in duration from first treatment.
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5 (A)

5 (B)
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5 (C)

5 (D)
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Figure 5: YPEL3 mRNA is induced after 24 hours of TSA/SAHA single-dose
treatment in MCF-7 but not in T-47D or ZR-75.1 cells. (A) Schematic representation
of work outline and HDACI doses for single dose 24A: cells were plated 16-24 hours
before treatment in (6-well) plates and each well received one sort of treatment. Cells
were then treated a single time with the respective doses of DMSO, TSA, or SAHA and
total RNA was isolated 24 hours after treatment. (B) MCF-7 YPEL3 mRNA elevates in
response to 70 nM TSA (~ 2-fold), 280 nM TSA (> 5-fold), & 5 µM SAHA (3-fold). (C)
& (D) T-47D and ZR-75.1 cells, respectively, do not show a consistent increase in
YPEL3 mRNA in response to TSA/SAHA single-dose treatment after 24 hours. Error
bars represent 95% confidence intervals.
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TSA doses of 70 nM and 280 nM were retained in this second dosing system to serve as
repeats for MCF-7 results as outlined in Figure 6A. Consistently, MCF-7 cells showed an
induction in YPEL3 expression in response to 70 nM TSA and 280 nM TSA (4-fold
induction for each), 5 µM SAHA (5-fold) as well as 25 µM SAHA (3-fold) (Figure 6B),
while neither T-47D or ZR-75.1 cells showed a consistent induction of YPEL3 mRNA
following 24 hours of treatment at the indicated doses (Figures 6C & 6D).
I also examined YPEL3 expression forty-eight and seventy-two hours following
single dose administration of TSA (70 nM & 280 nM) and SAHA (1 µM, 5 µM, & 25
µM) according to outlines in Figures 7A (for single-dose 48-hour treatment) and 8A (for
single-dose 72-hour treatment). Sustained YPEL3 induction was observed in MCF-7 cells
treated with the high doses of the HDACIs TSA (280 nM) and SAHA (25 µM) following
48 and 72 hour single-dose treatment (Figures 7B & 8B). T-47D cells, likewise, showed a
significant induction of YPEL3 expression following 280 nM TSA and 5 µM SAHA 48hour treatment (Figure 7C) and with the high doses only (280 nM TSA & 25 µM SAHA)
after 72 hours. ZR-75.1 cells did not show a correspondent YPEL3 induction to any of
the doses at either 48- or 72-hour time points (Figures 7D & 8D, respectively).
The cell culture half-life for TSA and SAHA has been reported to be around 24
hours (unpublished data), which might explain why doses in the recommended range (70
nM for TSA and 2.5-5.0 µM for SAHA) do not sustain YPEL3 mRNA induction after 48
or 72 hours of single dose administration. To elicit continuous induction in YPEL3
mRNA, I set up the 48-hour and 72-hour chronic dosing systems where cells are treated
every 24 hours for 48 and 72 hours, respectively (Table 3). In the 48-hour chronic dose
treatment regimen, total RNA was isolated following the administration of two
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6 (B)
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6 (C)
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Figure 6: YPEL3 mRNA is induced after 24 hours of TSA/SAHA single-dose
treatment in MCF-7 but not in T-47D or ZR-75.1 cells. (A) Table of TSA/SAHA new
dosage regimen and a schematic of work outline for single dose 24B: cells were plated
16-24 hours before treatment in (6-well) plates and each well received one sort of
treatment. Cells were then treated a single time with the respective doses of DMSO, TSA,
or SAHA and total RNA was isolated 24 hours after treatment. (B) MCF-7 YPEL3
mRNA elevates in response to HDAC inhibitors TSA: 4-fold (70 nM and 280 nM TSA),
and SAHA: 5-fold (5 µM SAHA) and 3-fold (25 µM SAHA). (C) & (D) T-47D and ZR75.1 cells, respectively, fail to show a parallel increase in YPEL3 mRNA in response to
TSA/SAHA single-dose treatment after 24 hours. Error bars represent 95% confidence
intervals.
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7 (B)
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7 (C)

7 (D)
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Figure 7: YPEL3 mRNA is induced after 48 hours of TSA/SAHA single-dose
administration in MCF-7 and T-47D but not in ZR-75.1 cells. (A) Schematic
representation of work outline and HDACI doses for single dose 48-hour treatment
regimen: cells were plated 16-24 hours before treatment in (6-well) plates and each well
received one sort of treatment. Cells were then treated a single time with the respective
doses of DMSO, TSA, or SAHA and total RNA was isolated 48 hours after treatment.
(B) MCF-7 YPEL3 mRNA elevates 5-fold and 2.5-fold following 280 nM TSA and 25
µM SAHA single-dose administration, respectively. (C) Comparable induction of YPEL3
mRNA in T-47D cells in response to 280 nM TSA (~ 5-fold) and 5 µM SAHA (~ 3-fold).
(D) No consistent induction of YPEL3 expression in ZR-75.1 cells forty eight-hours
following TSA/SAHA single-dose treatment. Error bars represent 95% confidence
intervals.
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8 (C)
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Figure 8: YPEL3 mRNA is induced after 72 hours of TSA/SAHA single-dose
treatment in MCF-7 and T-47D but not in ZR-75.1 cells. (A) Schematic representation
of work outline and HDACI doses for single dose 72-hour treatment regimen: cells were
plated 16-24 hours before treatment in (6-well) plates and each well received one sort of
treatment. Cells were then treated a single time with the respective doses of DMSO, TSA,
or SAHA and total RNA was isolated 72 hours after treatment. (B) YPEL3 mRNA is
induced in MCF-7 cells in response to 280 nM TSA (> 2-fold) and 25 µM SAHA (~ 4fold) compared to DMSO treated cells. (C) Parallel YPEL3 mRNA induction in T-47D in
response to 280 nM TSA (>2-fold) and 25 µM SAHA (>10-fold). (D) ZR-75.1 cells did
not show a consistent increase in YPEL3 mRNA in response to TSA/SAHA single-dose
treatment after 72 hours. Error bars represent 95% confidence intervals.
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consecutive doses of DMSO, TSA, or SAHA with 24-hour intervals and RT-PCR was
performed to examine YPEL3 expression as shown in Figure 9A. In MCF-7 cells,
YPEL3 mRNA was induced 2.5-5 folds in response to the HDACI moderate doses
(70nM TSA, 5 µM SAHA) and high doses (280 nM TSA, 25 µM SAHA) as compare to
DMSO-treated MCF-7 cells (Figure 9B).
T-47D showed a parallel 2.5-5 fold induction of YPEL3 mRNA in this dosage
system as demonstrated in Figure 9C while ZR-75.1 cells did not show a consistent
induction of YPEL3 expression in the 48-hour chronic dosing system (Figure 9D).
Chronic dosing for 72 hours was set up in a similar manner where cells from the three
cell lines: MCF-7, T-47D, and ZR-75.1, were treated chronically with HDACIs for 72
hours as outlined in Figure 10A. This resulted in a more robust increase in YPEL3
expression in both MCF-7 and T-47D: the higher doses correlated with the strongest
induction of YPEL3 expression (more than 10-fold) and (about 4-fold) in response to 280
nM TSA and 25 µM SAHA in MCF-7 cells, respectively, and 7-8 fold in response to 280
nM TSA and 25 µM SAHA in T-47D cells. Moderate doses of TSA (70 nM) and SAHA
(5 µM) also associated with relatively high YPEL3 mRNA levels as compared to DMSOtreated cells for both MCF-7 and T-47D cells (Figures 10B & 10C). ZR-75.1 cells, again,
did not show any induction of YPEL3 mRNA in response to any of the doses in the 72hour chronic dosing system (Figure 10D).
Altogether, TSA (70 nM and 280 nM) and SAHA (5 µM and 25 µM) elevate
YPEL3 mRNA in MCF-7 cells twenty-four hours after treatment, and also following
chronic administration for forty-eight and seventy-two hours. This effect is retained only
for the high doses (280 nM TSA) and (25 µM SAHA) forty-eight and seventy-two hours
44

9(A)

9 (B)

45

9 (C)

9 (D)

46

Figure 9: YPEL3 mRNA is induced after 48 hours of TSA/SAHA chronic treatment
in MCF-7 and T-47D but not in ZR-75.1. (A) Schematic representation of work outline
and HDACI doses for chronic dose 48-hour treatment regimen: cells were plated 16-24
hours before treatment in (6-well) plates and each well received one sort of treatment.
Cells were then treated every 24 hours with the respective dose of DMSO, TSA, or
SAHA and total RNA was isolated 48 hours after treatment. (B) YPEL3 mRNA is
induced in MCF-7 cells > 2-folds when treated with 70 nM TSA, 5 µM SAHA, and 25
µM SAHA and ~ 5-folds when treated with 280 nM TSA for 48 hours. (C) YPEL3
mRNA is induced in T-47D cells ~ 2.5-folds in response to the moderate doses of
DHACIs (70 nM TSA and 5 µM SAHA) and approximately 4-5 folds in response to the
high doses (280 nM TSA and 25 µM SAHA). (D) ZR-75.1 cells did not show a consistent
increase in YPEL3 mRNA when treated chronically with TSA/SAHA for 48 hours. Error
bars represent 95% confidence intervals.
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Figure 10: YPEL3 mRNA is induced after 72 hours of TSA/SAHA chronic
treatment in MCF-7 and T-47D but not in ZR-75.1 cells. (A) Schematic representation
of work outline and HDACI doses for chronic dose 72-hour treatment regimen: cells
were plated 16-24 hours before treatment in (6-well) plates and each well received one
sort of treatment. Cells were then treated every 24 hours with the respective doses of
DMSO, TSA, or SAHA and total RNA was isolated 72 hours after treatment. (B, C) In
response to the moderate doses (70 nM TSA and 5 µM SAHA) and high doses (280 nM
TSA and 25 µM SAHA) of the HDACIs, YPEL3 mRNA is induced 3-10 fold in MCF-7
cells (B) and 2-7.5 folds in T-47D cells (C). (D) ZR-75.1 cells did not show a consistent
increase in YPEL3 mRNA after treating with any of the doses in the chronic dose 72hour treatment regimen. Error bars represent 95% confidence intervals.
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following single-dose administration since TSA and SAHA half-life (t½) in cell culture is
~ 24 hours. In T-47D cells, 24-hour treatment had no effect on YPEL3 expression. Yet,
induction following 48- and 72- hours of single and chronic dose administration was
observed and was consistent with the MCF-7 data. The ZR-75.1 cell line failed to show a
time- or dose- dependent induction of YPEL3 mRNA in any of the treatment regimens
designed for this project.
B. HDACI treatment is Associated with Increased Premature Cellular Senescence in
MCF-7 Breast Cancer Carcinoma Cells
Since YPEL3 has been reported by our laboratory to induce premature cellular
senescence in both primary and tumor cells (Kelley et al., 2010), I sought to investigate
the biological significance of HDACI-induced YPEL3 expression. This was tested by
first examining whether HDACI treatment is able to trigger premature cellular
senescence in MCF-7 cells, and second, if present, examine the dependence of this
senescence on YPEL3. I set up 48- and 72- hour chronic treatment experiments with
MCF-7 cells as outlined in Figures 11A & 12A, respectively. In the previous experiments
examining YPEL3 expression following different doses/time points of HDACI treatment,
we noted that the high doses of TSA (280 nM) and SAHA (25 µM) correlated with the
highest induction of YPEL3 mRNA. These doses were also associated with significant
cell death. This is expected as it has been reported that TSA and SAHA induce cellular
apoptosis through multiple mechanisms (Dokmanovic et al., 2007). At high doses,
cytotoxicity would affect both primary and tumor cells, which limits the clinical
significance of such doses. Therefore, for our senescence experiments, we decided to use
lower TSA (70 nM and 140 nM) and SAHA (5 µM and 10 µM) doses that associated
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with YPEL3 mRNA induction and at the same time would allow us to uncover any
potential growth arrest or senescence-triggering effects at these doses.
Charcoal-stripped serum (CSS) treatment has been shown by our laboratory to
trigger premature senescence in MCF-7 cells when applied for 3-5 days (Tuttle et al.,
2012), and thus was used as a positive control for our experiments. Cells to be treated
with the HDACIs or CSS were plated at a high density (400,000 to 500,000 cells) as
compared to cells to be treated with DMSO (150,000 cells). For our 48- and 72- hour
treatment conditions, we assayed senescence by looking at senescence-associated βgalactosidase (SA-β-gal) activity at pH = 6.0, which is the most widely used marker of
cellular senescence (Dimri et al., 1995).
MCF-7 cells were treated with HDACIs for 48 and 72 hours and the percentage of
senescent cells was determined and compared to the DMSO treated cells (as the negative
control) and CSS-treated cells (as the positive control). Forty-eight hours post-treatment,
49% of MCF-7 cells treated with 70 nM TSA and 58% of cells treated with 140 nM TSA
stained positive for senescence as compared to 22% of DMSO treated cells (Figures 11B
& 11C). The senescence associated with DMSO treatment could be accounted for by the
fact that MCF-7 cells with wt YPEL3 display basal cellular senescence in the range of 540% depending of the plate confluency, described as contact-inhibition growth arrest
(unpublished, Kelly Miller). SAHA treated cells also exhibited increased senescence
(42% and 46%) in response to 5 µM and 10 µM SAHA, respectively (Figures 11B &
11C). CSS treated cells for 48 hours presented a similar percentage of senescence
compared to DMSO treatment, which is expected since CSS treatment needs at least 72
hours to trigger senescence in MCF-7 cells (personal communication, Steven Berberich).
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Figure 11: HDACI 48-hour treatment increases premature senescence in MCF-7
breast carcinoma cells. (A) Schematic of HDACI doses and work outline for examining
48-hour chronic TSA/SAHA treatment effect on MCF-7 premature cellular senescence.
Cells were plated 16-24 hours prior to treatment in (6-well) plates and each well received
one sort of treatment. Cells were then treated every 24 hours with DMSO, CSS, TSA, or
SAHA and SA-β-gal assay was performed at the end of 48-hour period. (B)
Representative images from each treatment condition taken at 100X magnification. (C)
Representative images of cells considered senescent (red arrows) compared to nonsenescent cells (yellow arrows). (D) Histogram representing average % of βgalactosidase positive cells where at least 100 cells were counted for each treatment
condition.
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Seventy-two hour chronic HDACI-treatment of MCF-7 cells was also set up
according to outline in Figure 19A. TSA and SAHA induced senescence in MCF-7 cells
in response to 70 nM TSA (47%), 140 nM TSA (54%), 10 µM SAHA (45%) and 5 µM
SAHA (54%) as compared to DMSO treatment (22%) (Figures 12B & 12C). Treatment
of MCF-7 cells with CSS for 72 hours resulted in the expected increase in senescence
(45%). On the whole, I was able to observe that HDACI 48- and 72- hour chronic
treatment triggers premature cellular senescence in MCF-7 cells. Subsequently, I sought
to investigate the dependence of this senescence on YPEL3.
C. HDACI Senescence Induction is Dependant on YPEL3 in MCF-7 Cells
TSA and SAHA are global HDAC inhibitors that target Class I and II HDACs for
inhibition (Dokmanovic et al., 2007). Therefore, these chemicals potentially affect
numerous cellular pathways that might lead to senescence activation. To determine
whether the observed HDACI-induced premature cellular senescence was dependent on
YPEL3, shYPEL3 lentivirus was used to infect MCF-7 cells and generate MCF-7 with
YPEL3 null background. Using this approach, we were able to knockdown endogenous
YPEL3 to > 90% on the mRNA level as compared to shCON (Figure 13A). shCON
lentivirus was used to infect MCF-7 cells and generate MCF-7 shCON cells. MCF-7
shYPEL3 and MCF-7 shCON cells were subjected to 48- and 72-hour TSA/SAHA
chronic treatment (Figures 13B and 14A, respectively). Subsequently, an SA-β-gal assay
was performed to examine whether TSA or SAHA is able to trigger senescence through
cellular pathway(s) independent of YPEL3. Forty-eight hour treatment experiment with
complete media (CM), 140 nM TSA, and 10 µM SAHA indicated increased senescence
in MCF-7 shCON cells treated with 140 nM TSA (45%) and 10 µM SAHA (56%)
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Figure 12: HDACI 72-hour treatment increases premature senescence in MCF-7
breast carcinoma cells. (A) Schematic of HDACI doses and work outline for examining
72-hour chronic TSA/SAHA treatment effect on MCF-7 premature cellular senescence.
Cells were plated 16-24 hours prior to treatment in (6-well) plates and each well received
one sort of treatment. Cells were then treated every 24 hours with DMSO, CSS, TSA, or
SAHA and SA-β-gal assay was performed at the end of 72-hour period. (B)
Representative images from each treatment condition taken at 100X magnification. (C)
Histogram representing average % of β-galactosidase positive cells where at least 100
cells were counted for each treatment condition.
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as compared to MCF-7 shCON cellular basal senescence in CM (16%) (Figure 13C).
MCF-7 shYPEL3 cells, on the other hand, did not show an increase in senescence in
response to treatment with 140 nM TSA (11%) or 10 µM SAHA (13%) as compared to
CM-treated shYPEL3 MCF-7 cells (14%) (Figure 13D). The results of 48-hour HDACI
chronic-treatment presented in Figure 20 indicate that the absence of YPEL3 can block
HDACI-induced premature cellular senescence in MCF-7 cells. In the same way, 72-hour
chronic treatment with HDACIs was set up for MCF-7 shCON and MCF-7 shYPEL3
cells (Figure 14A) and senescence was detected in 51% of MCF-7 shCON cells treated
with 140 nM TSA and 54% of MCF-7 shCON cells treated with 10 µM SAHA as
compared to MCF-7 shCON grown in complete media (basal senescence = 15%). In
contrast, TSA/SAHA 72-hour chronic treatment of MCF-7 shYPEL3 cells failed to
trigger senescence as compared to MCF-7 shYPEL3 cells grown in CM (Figures 14B &
14C). These results suggest that HDACI-induced premature cellular senescence in MCF7 cells is dependent on the presence of YPEL3.
D. HDAC3 Does Not Appear to Be Involved in YPELs Repression in Breast Carcinoma
Cell Line MCF-7
During the course of the previous experiments, we were contacted by Dr. Jinsong
Zhang (Department of Cancer Biology, University of Cincinnati College of Medicine)
with some data regarding YPEL3. In summary, Dr. Zhang’s laboratory has been working
with MCF-7 cells where different shRNAs were used to deplete HDAC3 or its binding
proteins, namely NCoR (nuclear receptor co-repressor protein) or SMRT (silencing
mediator for retinoid and thyroid hormone receptors). Messenger RNA from these
samples was used for sequencing experiments to determine the genes affected by specific
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Figure 13: HDACI 48-hour treatment induces YPEL3-dependent premature
senescence in MCF-7 breast carcinoma cells. (A) RT-PCR analysis showing YPEL3
mRNA knock-down in MCF-7 cells infected with shYPEL3 compared to MCF-7 shCON.
Error bars represent 95% confidence intervals. (B) Schematic of HDACI doses and work
outline for examining YPEL3 dependence of 48-hour TSA/SAHA induced premature
senescence in MCF-7 cells. MCF-7 shCON and shYPEL3 cells were generated, plated
16-24 hours prior to treatment in (6-well) plates where each well received one sort of
treatment. Cells were then treated every 24 hours with CM, TSA, or SAHA and SA-β-gal
assay was performed at the end of 48-hour period. (B) Representative images of MCF-7
shCON cells from each treatment condition taken at 100X magnification. (C)
Representative images of MCF-7 shYPEL3 cells from each treatment condition taken at
100X magnification. (D) Histogram representing average % of β-galactosidase positive
cells where at least 100 cells were counted for each treatment condition.
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Figure 14: HDACI 72-hour treatment induces YPEL3-dependent premature
senescence in MCF-7 breast carcinoma cells. (A) Schematic of HDACI doses and
work outline for examining YPEL3 dependence of 72-hour TSA/SAHA induced
premature senescence in MCF-7 cells. MCF-7 shCON and shYPEL3 cells were
generated, plated 16-24 hours prior to treatment in (6-well) plates and each well received
one sort of treatment. Cells were then treated every 24 hours with CM, TSA, or SAHA
and SA-β-gal assay was performed at the end of 72-hour period. (B) Representative
images of MCF-7 shCON cells from each treatment condition taken at 100X
magnification. (C) Representative images of MCF-7 shYPEL3 from each treatment
condition taken at 100X magnification. (D) Histogram representing average % of βgalactosidase positive cells where at least100 cells were counted for each treatment
condition.
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lentiviral knock-downs. Dr. Zhang observed that YPEL3 appeared to be induced upon
HDAC3 knockdown in MCF-7 cells (unpublished, Jinsong Zhang). Therefore, I sought to
investigate the possible involvement of HDAC3 in YPEL3 repression in ER-α positive
breast cancer cell lines. According to this model, estrogen crosses the cell membrane and
binds its ER-α. The bound ER-α forms homo- or hetero- dimers and acts as a
transcription factor recruiting a co-repressor complex (involving HDAC3) to the YPEL3
promoter, thereby directly repressing YPEL3 expression (Figure 15A). Binding of this
co-repressor complex hypothetically occurs at either the complete ERE (with 2 half-sites)
30 kbp upstream of the YPEL3 transcription start site, or at the ERE half-site 3.6 kbp
downstream of the transcription start site in the 3’ untranslated region of the gene (Figure
15B). We termed this model the direct HDAC repression hypothesis as it presumably
involves an HDAC directly participating in an ER-α recruited co-repressor complex to
repress YPEL3 expression.
A lentivirus producing an shRNA targeting the HDAC3 gene (shHDAC3 pLKO)
was purchased and used to knock-down HDAC3 in MCF-7 cells. MCF-7 cells were
plated at 150,000 cells and were infected with shHDAC3, shCON or ER-α and selected
with puromycin for 4 days. Pooled MCF-7 cells stably selected for expression of
shHDAC3, shER-α, or control (shCON) were used for total RNA isolation and RT-PCR
experiments to examine YPEL3 expression. In three independent experiments, the knockdown of HDAC3 in MCF-7 cells did not induce YPEL3 expression at the mRNA level
(Figure 16A) as compared to the knock-down of ER-α, which has been previously
reported by our laboratory to elevate YPEL3 mRNA and protein expression (Tuttle et al.,
2012) and is shown in Figure 16A to induce YPEL3 mRNA expression 5-folds. HDAC3
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Figure 15: Schematic representation of the direct HDAC repression hypothesis. (A)
Drawing depicts the model where 17-β estradiol crosses the cell membrane, binds it ER-α
and forms homodimers with other estrogen-bound ER-α. These homodimers act as
transcription factors recruiting co-repressor complexes to the YPEL3 promoter to directly
inhibit YPEL3 expression. In this figure, the repressor complex is shown to bind the
distant ERE upstream of the YPEL3 promoter. (B) Schematic representation of the
YPEL3 gene and locations of the putative ERE sites. The repressor complex recruited by
homo- or hetero- dimers of the bound ER-α may involve HDAC3 and may bind at either
complete ERE site 30 kbp upstream of the YPEL3 transcription start site or at the ERE
half-site downstream of the YPEL3 transcription start site, in the 3’UTR of the YPEL3
gene.
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Figure 16: HDAC3 does not appear to be involved in YPEL3 repression. (A) Relative
expression of YPEL3 normalized to GAPDH in MCF7 shCON, MCF7 shHDAC3, and
MCF7 shER-α cells. (B) Relative expression of HDAC3 normalized to GAPDH in MCF7
shCON and MCF-7 shHDAC3 cells showing HDAC3 knock-down on the mRNA level.
(C, left) Western blot confirming HDAC3 knock-down in MCF-7 shHDAC3 cells as
compared to MCF-7 shCON cells. (C, right) Histogram showing quantification of the
HDAC3 protein levels from the western blot, after normalizing to β-actin. Error bars
represent 95% confidence intervals.
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mRNA knock-down in MCF-7 cells was examined by RT-PCR for the 3 independent
experiments (consistent ~ 80% knock-down) (Figure 16B). It was necessary to prove that
mRNA knock-down of HDAC3 corresponded with an effect on HDAC3 protein levels.
Therefore, I performed western blotting with protein extracts from MCF-7 shHDAC3 and
shCON cells. I observed that HDAC3 protein levels were reduced by ~ 40% in MCF-7
shHDAC3 cells compared to MCF-7shCON cells (Figure 16C). Based on these data, I
conclude that HDAC3 does not appear to participate in the repression of YPEL3 in MCF7 breast carcinoma cells.
E. HDACIs Induce YPEL3 Expression through ER-α Down-regulation
Since it did not appear that HDAC3 was involved in YPEL3 repression, I sought
to examine whether HDACI treatment is actually affecting the estrogen-bound ER-α,
which has been shown by our laboratory to repress the YPEL3 gene. This idea was
supported by the findings of one study that reported TSA treatment led to downregulation of the estrogen receptor alpha. ER-α was described to be down-regulated at the
mRNA and protein levels 4 hours after high-dose TSA administration (Duong et al.,
2006). I wanted to examine whether the TSA/SAHA doses that associated with elevated
YPEL3 mRNA and mediated senescence produced any effects on ER-α mRNA and/or
protein levels. In such case, this effect would be analogous to our previous reports of
YPEL3 induction upon ER-α knockdown in MCF-7 cells (Tuttle et al., 2012). I set up the
experiments where complete media- and DMSO- treated MCF-7 cells (plated at 150,000
cells) and HDACI-treated MCF-7 cells (plated at 400,000 to 500,000 cells) were treated
chronically for 48 and 72 hours with 140 nM TSA and 10 µM SAHA. Multiple wells
were set up for each TSA/SAHA treatment condition for RNA isolation and western blot
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analysis since we observed that treatments induced significant cell death. RT-PCR
analysis showed that 48 and 72 hours post chronic treatment, ER-α mRNA was
significantly down-regulated in response to 10 µM SAHA but not 140 nM TSA for at
least two independent experiments (Figure 17A and 17B). To examine the effects of these
treatments on ER-α protein levels, I performed a western blot with protein extracts from
MCF-7 cells chronically treated with 140 nM TSA and 10 µM SAHA for 48 hours. I used
MDA-MB-231 and SkBr-3 breast adenocarcinoma cell lines as negative controls (they
both are ER-α negative). Surprisingly, treatment with both TSA and SAHA significantly
down-regulated ER-α protein levels following 48-hour chronic treatment in MCF-7 cells
compared to MCF-7 cells grown in complete media or DMSO-treated MCF-7 cells
(Figure 17C). These results suggest that SAHA elevates YPEL3 mRNA by downregulating ER-α mRNA and protein levels whereas TSA lowers protein levels of ER-α in
what seems like a post-transcription effect only. In summary, treatment of MCF-7 cells
with both global HDACIs TSA and SAHA down-regulates ER-α protein levels. Only
SAHA was observed to repress ER-α mRNA expression while TSA did not appear to
affect the ER-α transcription in our experimental conditions. These findings gave rise to
our TSA/SAHA indirect YPEL3-repression model where HDACI-treatment of MCF-7
cells elevates YPEL3 mRNA and its dependent-senescence through the down-regulation
of ER-α mRNA and/or protein levels (Figure 18). This model provides at least one
explanation for the observed up-regulation of YPEL3 mRNA expression and dependentsenescence in MCF-7 cells and is consistent with our laboratory’s most recent report of
estrogen repression of YPEL3 in an ER-α dependent manner in MCF-7 breast carcinoma
cells (Tuttle et al. 2012).
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Figure 17: Chronic treatment with TSA/SAHA down-regulates the ER-α protein
levels, while only SAHA inhibits ER-α mRNA expression. Relative mRNA expression
of ER-α normalized to GAPDH in MCF7 shCON cells chronically treated with complete
media, DMSO, 140 nM TSA or 10 µM SAHA for 48 hours (A) or 72 hour (B). Error bars
represent 95% confidence intervals (C, top) Western blot showing ER-α knock-down in
MCF-7 cells treated with TSA or SAHA as compared to MCF-7 cells grown in CM,
MCF-7-DMSO, and the ER-α negative breast cancer cell lines MDA-MB-231 and SkBr3 cells. (C. bottom) Histogram shows quantification of ER-α protein levels shown on the
western blot after normalization to β-actin.
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Figure 18: Schematic representation of TSA/SAHA indirect repression hypothesis.
TSA and SAHA act on ER-α protein to down-regulate its levels so that less ER-α is
available in the cell to repress YPEL3.
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IV. Discussion
The YPEL3 gene is a p53-target gene reported to be repressed by estrogen in ERα positive breast cancer cells. Estrogen repression of YPEL3 in MCF-7 breast carcinoma
cells (ER-α positive, wt p53) was shown to be ER-α dependent and p53-independent and
is believed to be directly mediated by the binding of estrogen-bound ER-α at a putative
ERE upstream and/or downstream of the YPEL3 promoter (Tuttle et al., 2012). This
study was designed to identify potential histone-deacetylation mechanisms associated
with estrogen repression of YPEL3 in MCF-7 breast carcinoma cells. Global HDAC
inhibitors TSA and SAHA induced YPEL3 mRNA expression in MCF-7 cells following
24 hours of administration in a dose-dependent manner. Chronic administration for 48 or
72 hours produced a parallel induction of YPEL3 expression, while this effect was
retained only for the higher doses following 48 or 72 hours of single dose-administration.
The latter is explained by the TSA and SAHA t½ being around 24 hours in cell culture,
so that only higher doses would retain adequate drug material to affect YPEL3 expression
at time points subsequent to 24 hours.
Because YPEL3 induction was demonstrated by our laboratory to trigger
premature cellular senescence in both primary and tumor cells (Kelly et al., 2010), the
next step in the project was set up to examine whether YPEL3 induction resulting from
HDACI treatment had any biological significance in MCF-7 cells, i.e. in terms of
triggering premature cellular senescence. Indeed, experiments examining senescence
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associated β-galactosidase activity 48 and 72 hours following TSA/SAHA treatment in
MCF-7 cells, documented a significant increase in senescence in these cells following
treatment. To determine the dependence of this senescence on YPEL3, MCF-7 cells
knocked down for YPEL3 were subjected to the same treatment conditions and
senescence was assayed subsequently. We observed that the knock-down of YPEL3 is
able to block HDACI-mediated senescence, as demonstrated by the inability of MCF-7
shYPEL3 cells to display increased senescence in response to HDACI treatment. In
essence, TSA and SAHA treatment induced YPEL3 expression and dependentsenescence in MCF-7 cells, and subsequent experiments of the project aimed at
elucidating the mechanism(s) through which TSA and SAHA affect the YPEL3 gene.
Studies of nuclear receptor signaling led to the identification of co-activators and
co-repressors that control transcriptional activation or repression. In particular, corepressors have frequently been reported to mediate the active repression of gene
transcription through the recruitment of enzymes to covalently modify histone tails (Nagy
at al. 2004; Sonoda et al., 2008). Given that TSA and SAHA treatment induced YPEL3
expression in MCF-7 cells and these global HDACIs are documented to inhibit the 10
members of Class I and II of the HDAC family (HDAC1 through HDAC10), and the fact
that we have evidence suggestive of a direct repression of YPEL3 by estrogen, the next
step in the project was designed to investigate the possible involvement of HDACs in
estrogen mediated repression of YPEL3 in MCF-7 cells. The model we envisioned
involved a co-repressor HDAC complex recruited by the estrogen bound-ER-α to
either/both EREs in YPEL3 promoter proximal and/or distant regions.
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Of all the 10 candidates HDAC1 through HDAC10, we started our search with
HDAC3. HDAC3 significance in co-repressors comes from it being the primary histone
deacetylase in SMRT/NCoR complexes (Guenther et al., 2001) which are the first
identified nuclear receptor co-repressors (Chen et al., 1995; Sande et al., 1996; Ordentlich
et al., 1999; Park et al., 1999). In addition, it was reported to us by an independent
investigator to potentially play a role in YPEL3 repression. The basic layout of
experiments supporting that conclusion from the independent investigator laboratory
involved infecting MCF-7 cells with shHDAC3 and then isolating and massively
sequencing the mRNA from these cells. The experiments we designed to investigate this
hypothesis involved infecting MCF-7 cells with shHDAC3, isolating total RNA and
examining YPEL3 expression through RT-PCR. Results from at least three independent
experiments didn’t support these conclusions because the knock-down of HDAC3 in
MCF-7 cells did not induce YPEL3 expression.
In order to account for opposing results from these two experiments, we contacted
the independent investigator for more comprehensive experimental conditions. It turned
out that MCF-7 cells used for the mRNA sequencing experiments were grown under
charcoal-stripped medium and estrogen was added to the medium two hours before cell
lysis (unpublished, Zhang, 2010). Therefore, we believe that YPEL3 induction in these
experiments might be due to CSS treatment rather than HDAC3 knock-down. A future
experiment to test this speculation would involve adding back estrogen for at least 8
hours prior to cell lysis and mRNA sequencing. This time was reported by our laboratory
to be the minimum time required for estrogen to have its full repression effect on YPEL3,
when added back to MCF-7 cells grown in CSS. Looking at YPEL3 mRNA at this 8-hour
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time point in MCF-7 cells with specific HDAC knock-downs would probably identify the
critical HDAC that is essential for ER-α mediated repression.
In addition, literature reports other HDACs to interact with SMRT or NCoR
complexes, including class II HDACs 4, 5 and 7 and class I HDACs 1 and 2, but their
roles in SMRT- and NCoR-mediated gene repression is not clearly identified (Alland et
al., 1997; Heinzel et al., 1997; Nagy et al., 1997). All of these HDACs are inhibited by
TSA and SAHA and anyone could be the principal HDAC involved in YPEL3 repression
in MCF-7 cells. We don’t know if the co-repressor is able to form in the absence of
HDAC3 in MCF-7 cells and mediate YPEL3 repression by action of any of these other
HDACs. Future experiments for this project in the quest of identifying the principal
HDAC or group of HDACs participating in YPEL3 repression in MCF-7 cells, would
involve generating MCF-7 cells with knock-downs for specific HDACs through shRNA
approaches, and examining YPEL3 expression through RT-PCR or mRNA sequencing
experiments. From there we could go further to investigate our HDAC direct repression
model, by first examining the histone acetylation around the YPEL3 promoter in
response to HDACI treatment, and second looking at the presence of a specific
HDAC/ER-α co-repressor at either/or the putative EREs in the YPEL3 gene using
chromatin immuno-precipitation (CHIP) experiments.
In this study we report one mechanism by which HDACI treatment triggers
YPEL3 mRNA expression (and consequently its dependent premature cellular
senescence) in MCF-7 cells. This mechanism of YPEL3 up-regulation is manifested by
TSA and SAHA down-regulation of ER-α protein levels. These observations gave rise to
our TSA/SAHA indirect repression hypothesis where TSA and SAHA act on ER-α
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protein for degradation regardless of the ER-α co-repressor complex involving an HDAC
or not. This finding is consistent with our laboratory previous report of YPEL3 repression
in MCF-7 cells being ER-α dependent. While TSA and SAHA both down-regulate ER-α
protein levels, only SAHA was found to inhibit ER-α mRNA levels. In our experiments,
TSA appears to increase the proteosomal degradation of ER-α protein without affecting
transcription of the gene. A future experiment to conclude our TSA/SAHA indirect
repression model would involve treating MCF-7 cells with HDACIs, then lentivirally
over-express ER-α to examine if this over-expression is able to block YPEL3 mRNA
induction and dependent senescence mediated by HDACI treatment. Because breast
cancer cells expressing the ER-α actually depend on estrogen action on ER-α for
proliferation and malignancy, further exploring the inhibiting effect of TSA/SAHA on
ER-α mRNA/protein may provide powerful insight into providing a specific HDAC
target/targets for a new class of mechanism-specific drugs in the treatment of breast
cancer.
In this project, three cell lines were assayed for YPEL3 expression following
HDACI-treatment: MCF-7 (ER-α positive, wt p53), T-47D (ER-α positive, mutant p53),
and ZR-75.1 breast carcinoma cells (ER-α positive, wt p53). In none of the dosing
regimens we followed in this project, did ZR-75.1cells show a consistent dose- or timedependent induction in YPEL3 mRNA. While we do not currently have a model to
explain this set of data, a future direction for our study will look further into YPEL3
response to HDACI in ZR-75.1cells first by examining the literature for an HDACI target
gene that has been documented to respond to HDACI treatment to make sure our doses
and time points are effective in these cells. Secondly, we will examine whether HDACI
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treatment is producing an effect on ER-α mRNA and/or protein levels in ZR-75.1cells,
since our laboratory has previously reported that CSS treatment efficiently elevates
YPEL3 mRNA expression in these cells (Tuttle et al., 2012). Looking into HDACI
treatment effect on ER-α in ZR-75.1 cells will possibly illustrate to us if MCF-7 findings
(ER-α inhibition being essential for YPEL3 induction) apply to ZR-75.1 cells. This might
also provide evidence to whether estrogen represses YPEL3 through ER-α independent
mechanisms in ZR-75.1 cells (ER-α being down-regulated by HDACI treatment, yet no
YPEL3 induction) provided we confirm by knocking down ER-α in ZR-75.1 cells and
looking into YPEL3 mRNA expression. HDACI treatment effect on YPEL3 in T-47D
cells (ER-α positive, mutant p53) paralleled MCF-7 data for the chronic- and single- dose
48 and 72 hour time points but not for the 24 hour time point. There are two paths we
plan to undertake to inspect the observed delay in T-47D cells. First, we will look into
ER-α mRNA and/or protein levels 24, 48 and 72 hours following HDACI treatment (to
see if our model for MCF-7 cells stands for T-47D cells). Second, we do not know if this
delay in YPEL3 induction is due to the fact that T-47D cells are p53 mutant. Therefore,
we will generate MCF-7 cells knocked down for p53 (MCF-7 shp53) and subject them to
HDACI treatment for 24 hours, then check for YPEL3 mRNA expression. An induction
in YPEL3 in MCF-7 shp53 cells in response to treatment will indicate the model in T47D cells to be p53-independent. In essence, our conclusions and future direction
experiments for this project are aiming to characterize the mechanisms of YPEL3
repression in relation to histone deacetylation in breast cancer cell lines. Of all the
epigenetic mechanisms documented to play roles in tumorigenesis, histone deacetylation
is the most extensively linked to drug discovery. Understanding YPEL3 induction and
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associated senescence in response to HDACIs in breast cancer cells will help identify
novel approaches to trigger senescence in these tumor cells. Simultaneously, these
approaches will be linked to clinical practice with the ultimate aim of translating these
abstract facts into new therapeutic options for breast cancer patients.
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